Burden and clinical impact of ‘neglected’ transfusion-transmitted infections in Cameroon: A systematic review and meta-analysis Authors: Megane D. Malieuze Nanfah, Verónica M. Binam Nkot, Michel M. Yop Kite, Sandrine S. Beack Bayengue, Gertrude Bsadjo Tchamba, Alphonse G. Tandja, Brice L. Koloko, Elodie T. Ngo Malabo, Judith G. L. F. Ekwe Priso, Elisee L. Embolo Enyegue, Martin L. Koanga Mogtomo, Loick P. Kojom Foko, Rana Nagarkatti, Rana Nagarkatti, Rana Nagarkatti Published: 2026 ABSTRACT BackgroundBlood supply is a public health challenge in African countries. In Cameroon, blood selection guidelines focus on four viral and bacterial pathogens (HIV, hepatitis B and C viruses, Treponema pallidum) associated with transfusion-transmitted infections (TTIs). Other pathogens, often endemic (e.g., Plasmodium spp.), are not routinely screened in blood banks and are not included in blood safety guidelines or surveillance, despite their potential for transfusion transmission.Materials and MethodsHere, we conducted a systematic review and meta-analysis of prevalence, determinants, and clinical impact of ‘neglected’ pathogens, defined as pathogens not included in national blood safety guidelines (e.g., filaria, dengue virus, Toxoplasma gondii), in blood banks. Additionally, we identified the most urgent challenges and proposed actionable solutions to guide blood safety guidelines in the country.ResultsA total of 18 studies, covering ~12,500 donations, were included, with the bulk coming from donors living in three regions (Littoral, Northwest, Centre). Plasmodium parasite (68.4%) was the major studied pathogen, even though an evident publication bias was found (p = 0.004). The other pathogens included dengue virus (5.3%), T. gondii (5.3%), and HTLV-1 (5.3%). The filarial parasite Loa loa was consistently accidentally found. Even though there is no evidence of SARS-CoV-2-associated TTIs till now, the pooled proportion of this virus was 17.7%. The pooled proportions of infection in blood donors were 16.6% for Plasmodium spp. and 0.5% for Loa loa. There is a paucity of clinical impact studies on these ‘neglected’ TTIs, and the available literature suggests impaired levels of immunoglobulin E and albumin. We identified urgent challenges, including awareness among healthcare providers and policymakers, diagnostic and logistical constraints, and low microbial density infections, associated with neglected pathogen-related blood safety.ConclusionWe opine that providing more epidemiological evidence is crucial to address the above-mentioned challenges for guiding and guaranteeing blood safety in Cameroon. Introduction Blood transfusion is a medical intervention during which whole blood or its components (e.g., platelets) are taken from an individual (i.e., the donor) to another individual (i.e., the recipient). An estimated ~118.5 million blood donations, of which 40% were from developed regions, were recorded by the World Health Organization (WHO) [1]. Each year, several million lives are saved through blood transfusions, along with corollaries such as improved health and greater welfare. In practice, the reasons and recipient groups for blood transfusion are diverse between developing and developed areas. While blood transfusion is commonly administered in the elderly (~60% of all transfusions) in high-income countries, children under five years of age are the primary recipients in low-income countries [2]. Blood safety is crucial to guarantee efficient blood transfusion in recipients. Developing regions in Africa, the Americas, and Asia are striving to improve their blood transfusion practices and guidelines, given the increasing demand for blood [1]. Till now, especially in these regions, blood transfusion is associated with a higher risk of transfusion-transmitted infections (TTIs), which can compromise recipients’ health outcomes. Aside from their natural routes of transmission, several pathogens of diverse origins can be transmitted through blood transfusion. These include prions, viruses (e.g., hepatitis C and B viruses – HCV/HBV, human immunodeficiency virus – HIV), bacteria (e.g., Treponema pallidum), fungi (e.g., Candida spp.), and parasites (e.g., Plasmodium spp., Toxoplasma gondii) [3,4]. In practice, priority is generally given to HIV, HCV, HBV, and T. pallidum in Africa, especially in countries such as Cameroon. The main reason is the higher dangerousness, chronicity, and long-term deleterious impact on individuals. Little attention is given to other blood-transmitted pathogens, especially to Apicomplexans such as Plasmodium spp., and T. gondii. Other major life-debilitating pathogens (e.g., Loa loa, dengue virus, parvovirus B9, Candida spp., Histoplasma capsulatum, Cryptococcus neoformans) are also routinely overlooked in blood banks from health facilities of several countries (e.g., Cameroon, India), and not integrated in national blood safety policies and surveillance, despite their potential for transfusion transmission [4,5]. In addition, insufficient epidemiological data and a lack of integration into national blood safety policies and surveillance frameworks further contribute to their under-recognition and inadequate monitoring. Some of them, e.g., Plasmodium spp., T. gondii, are highly endemic in several parts of the globe, including Cameroon. These pathogens can survive for long periods in unscreened blood bags and asymptomatically in infected recipients. Plasmodium spp. parasites can provoke clinical malaria, often leading to severe malaria and deaths [6]. Given their clinical impact in the general population, it is also crucial to determine the blood transfusion risk associated with these ‘neglected’ pathogens in developing countries such as Cameroon. To date, to the best of the authors’ knowledge, there are no systematic reviews and meta-analyses (SRMA) on the epidemiology and clinical impact of these neglected TTIs in Cameroon. This review was designed to address this gap and propose solutions to the current identified blood transfusion-related challenges in Cameroon. Materials and methods Registration, guidelines, and ethics The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines were followed to write this review (S1 Table) [7]. The review protocol was submitted to PROSPERO for registration (CRD420251148257). Search strategy and eligibility The identification of potentially relevant papers was made through tailored search strategies using databases (PubMed, African Journals Online-AJOL, The Wiley Online Library, ScienceDirect, and ResearchGate), local and international repositories [i.e., local scientific journals (e.g., Health Sciences & Disease), scientific organizations (e.g., Cameroon Academy of Sciences), websites (e.g., WHO African website)], and engines (i.e., Google Scholar). The searches were conducted in English and French from 1st to 30th September 2025. Boolean operators (OR, AND) were combined with search terms to identify relevant papers. For instance, the following search strategy was submitted to PubMed: ((“Transfusion‑transmitted infection”[Title/Abstract] OR “transfusion transmissible infection”[Title/Abstract] OR “TTI”[Title/Abstract] OR “blood donor”[Title/Abstract] OR “blood donor screening”[Title/Abstract] OR “blood transfusion”[Title/Abstract] OR “blood transfusion‑associated infection”[Title/Abstract]) AND (“neglected”[Title/Abstract] OR “burden”[Title/Abstract] OR “clinical impact”[Title/Abstract] OR “prevalence”[Title/Abstract] OR “incidence”[Title/Abstract] OR “magnitude”[Title/Abstract]) AND (Cameroon[Affiliation] OR Cameroon[Title/Abstract] OR “Central Africa”[Mesh] OR “West Africa”[Mesh])). We included all peer-reviewed studies (cross-sectional, longitudinal, case reports, case series, and cohort) addressing the epidemiology of neglected TTIs (e.g., malaria, toxoplasma, Trypanosoma, filariasis, Brucella, leishmania, Borrelia, cytomegalovirus, Zika virus, Loa loa, Dengue virus, Parvovirus B9, Candida, Fusarium, Histoplasma capsulatum, Aspergillus, Cryptococcus neoformans, or Malassezia) in Cameroon, written in French and/or English, and published between 2006 and 2025. Studies published before 2006 were excluded from the analysis to ensure the relevance and comparability of findings, in terms of diagnostic technologies, blood safety protocols, and malaria control strategies. Even though there is no evidence of blood transfusion of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via human blood products [8], we have included it in the searches. Its natural history is still elusive, as witnessed by the significant number of papers published on its natural history till now. Thus, it would not be surprising that its ability to elicit TTIs is evidenced in the upcoming years. Conversely, qualitative studies, conference papers, abstracts, preprints, reviews, theses, editorials, letters, and reports were excluded from this analysis. Screening strategy and data extraction Titles and abstracts of papers were evaluated independently by three reviewers (MDMN, MMYK, and VMBN). At this stage, some studies were directly excluded. If eligible, full-texts were retrieved from the databases. For restricted papers, the corresponding author was contacted to provide the full text. The bibliography of relevant papers was checked to identify additional papers. The studies were selected by three authors (MDMN, MMYK, and VMBN), and any discrepancies were resolved through discussion with the supervising author (LPKF). Data of interest were extracted from each paper and entered into an Excel spreadsheet (Microsoft Office, USA). Methodological quality We used the Joanna Briggs Institute (JBI) Critical Appraisal tools to evaluate the quality and bias risk of eligible studies. The tools are designed to appraise studies based on their study design (e.g., cross-sectional, cohort, case series) [9]. Two reviewers evaluated the methodological quality of the included studies. Data management Extracted data from the studies included in the present SRMA were summarized using graphics, tables, narratives, and meta-analysis. All graphics and maps were generated using GraphPad v8.02 and QGIS v3.36.1. Data were extracted and presented at the most granular scale. For instance, if a study used three techniques to detect Plasmodium spp. parasites, then, findings on infection prevalence were considered as three independent data points. Regarding data on associated factors, only studies that performed adapted statistical analyses (e.g., logistic regression models, generalized estimating equations) were retained to extract estimators of the magnitude of association (e.g., odds ratios – OR). Meta-analysis We performed a meta-analysis of proportions using the prevalence data of each pathogen. Data extracted to compute pooled estimates were the total number of donors positive for a given pathogen and the total number of screened donors. A minimum of 2 studies was needed to perform meta-analyses, as previously recommended. Forest plots were used to depict pooled estimates using the OpenMeta[Analyst] software v0.24.1 and the online platform MetaAnalysisOnline.com [10]. Meta-analyses were performed using a random-effects model (DerSimonian-Laird approach) with the Hartung-Knapp adjustment to control heterogeneity, and the Freeman-Tukey double arcsine transformation to estimate and stabilize variance. This approach was preferred to logit transformation owing to variance instability when proportions approach 0 or 1, especially when computing pooled estimates for low endemic pathogens. The between-study heterogeneity was assessed and interpreted by computing I2 and performing the Cochran’s Q-test [11]. When appropriate, a subgroup and leave-one-out analyses were used to evaluate the impact of potentially confounding variables (e.g., screening test, donor type) on the pooled estimates. The Egger’s test for small-study effects and funnel plots were used to evaluate the publication bias [12]. All statistical analyses were considered significant for p-value < 0.05. Results Characteristics of the included studies A total of 531 records were identified via database search strategies, of which 186 were excluded. Thus, the full-texts of 345 records were screened for eligibility. Several records were excluded for various reasons (e.g., studies focused on HIV, HCV, HBC, and T. pallidum). Fifteen papers were judged eligible for the study, in addition to three papers identified after inspection of bibliographies. We therefore included 18 studies in the systematic review, of which 14 were relevant for meta-analysis (Fig 1A) [13–30]. Most of the studies were cross-sectional (94.4%), conducted in a single study site (94.4%), conducted in the town of Yaoundé (38.9%), and in a clinical setting (88.9%) (Fig 2 & Table 1). Regarding blood donors, 41.2% of studies included family and voluntary donors, and the donor type was not specified in 4 studies (Table 1). Plasmodium spp. parasites (68.4%) were mainly targeted in the included studies (Fig 1B), followed by the SARS-CoV-2 (10.5%). It should be noted that the filarial parasite Loa loa was accidentally found, i.e., its detection was not included in the predefined study protocols, by the authors of two included studies [26,28]. Peripheral blood film (PBF) (42.3%) and rapid diagnostic tests (RDT) (34.6%) were the main screening techniques (Fig 1C). The bias risk of the studies was good for four criteria related to the objective definition and measurement of exposure and outcome (i.e., clear description of inclusion criteria, valid and reliable diagnostic tools, and utilization of standard criteria to assess neglected TTIs). However, 94.4% of the studies failed to provide site details (i.e., related to blood transfusion), and 66.7% did not use an appropriate statistical analysis to correctly address their defined objectives (S2 Table). 10.1371/journal.pntd.0014378.t001Table 1Characteristics of studies included in the systematic review and meta-analysis.Year of data collectionDesignArea (Region of Cameroon)Level of urbanisationSettingNDonor typesWere the study subjects and the setting described in detail?Was there an appropriate statistical analysis?Ref.1995-2005Cross-sectionalDouala (LT)UrbanClinical + Community1513Family + Voluntary no no [13]2007Cross-sectionalYaoundé (CEN)UrbanClinical493Family + Voluntary no no [14]2014Cross-sectionalDouala (LT)UrbanClinical865Voluntary no no [23]Mbingo (NW)Rural + Suburban + Urban1305Mutengene (NW)Rural + Suburban + Urban889Banso (NW)Suburban + Urban11702015Cross-sectionalDouala (LT)UrbanCommunity179Voluntary no no [24]2015 - 2016Cross-sectionalBuea (SW)UrbanClinical1240Not specified no no [25]2017Cross-sectionalDouala (LT)UrbanClinical250Family + Voluntary yes yes [26]2014Cross-sectionalYaoundé (CEN)UrbanClinical265Family + Voluntary no no [27]2015 - 2016Cross-sectionalDouala (LT)UrbanClinical372Family + Voluntary no no [28]2019Cross-sectionalYaoundé (CEN)UrbanClinical310Family + Voluntary + Replacement no no [29]2018Cross-sectionalYaoundé (CEN)UrbanClinical256Voluntary no yes [30]2021Cross-sectionalBafoussam (W)UrbanClinical101Family + Voluntary + Paid no no [15]2020Cross-sectionalBamenda (NW)UrbanClinical493Voluntary no not applicable [16]2021 - 2022Cross-sectionalDouala (LT)UrbanClinical102Family + Voluntary no yes [17]2021Cross-sectionalYaoundé (CEN)UrbanClinical232Family + Voluntary no yes [18]2022Cross-sectionalYaoundé (CEN)UrbanClinical223Not specified no not applicable [19]Not specifiedCross-sectional & LongitudinalDschang (W)UrbanClinical252Not specified no no [20]2022Cross-sectionalBamenda (NW)UrbanClinical337Not specified no no [21]2023Cross-sectionalYaoundé (CEN)UrbanClinical200Family + Voluntary no no [22]CEN: Centre, LT: Littoral, NW: Northwest, SW: Southwest, W: West. Characteristics of studies included in the systematic review and meta-analysis. CEN: Centre, LT: Littoral, NW: Northwest, SW: Southwest, W: West. Study inclusion process as per PRISMA guidelines. AJOL: African Journals Online, ELISA: Enzyme-Linked Immunosorbent Assay, HIV: Human immunodeficiency virus, HBV: Hepatitis B virus, HCV: Hepatitis C virus, PBF: Peripheral blood film, PCR: Polymerase chain reaction, RDT: Rapid diagnostic test, RT-LAMP: Reverse transcription loop-mediated isothermal amplification, SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, TMA: Transcription-mediated amplification, WHO: World Health Organization. Map of Cameroon depicting the geographical distribution of the studies. The Cameroon basemap was downloaded from Natural Earth (Base layer of the map available from: http://www.naturalearthdata.com) and visualized using the QGIS software v3.36.1 (https://qgis.org/en/site/). The regions where the included studies are highlighted in magenta. The total number of studies in each region is shown in the yellow shape. The total number of studies is > 18 because one study was conducted in two regions. Pooled overall prevalence of neglected TTIs Meta-analysis to compute pooled overall proportions was possible for Plasmodium spp., L. loa, and SARS-CoV-2. The pooled proportion of Plasmodium spp. infection in blood donors was 16.6% (95%CI 10.1 – 24.2%, I2 = 97.6%, p < 0.001) (Fig 3A). Publication bias was identified across studies on Plasmodium spp. (p = 0.004) (S1 Fig). Higher estimates were found for SARS-CoV-2 infection (17.7%, 95%CI 0.0 – 100%, I2 = 85.2%, p = 0.009) (Fig 3B). In contrast, the pooled proportion of L. loa infection in blood donors was 0.5% (95%CI 0.1 – 1.1%, I2 = 0.0%, p = 0.90) (Fig 3C). Prevalence data for dengue virus (24.8%), human T-lymphotropic virus 1 (HTLV-1, 5.6%), and T. gondii (4.7%) were available for only one study each (Fig 3D). Pooled proportions of Plasmodium spp. (A), SARS-CoV-2 (B), and Loa loa (C) in blood donors. Prevalence of HTLV-1 and Dengue viruses in blood donors (D). 95%CI: Confidence interval at 95%, I2: Heterogeneity, HTLV-1: Human T-lymphotropic virus 1, SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, ELISA: Enzyme-Linked Immunosorbent Assay, RDT: Rapid diagnostic test. ***SARS-CoV-2 was included in the analysis, even though there is limited evidence of transfusion-transmitted infection cases with this virus via human blood products. However, we kept this virus in the analysis, given the many dark areas of the natural history of this virus. Pooled proportion of Plasmodium spp. by confounding variables We evaluated the impact of variables (i.e., period of data collection, towns, region, setting, screening test, and sample size) on the pooled estimates of Plasmodium spp. infection. Lower proportions were observed in data collected before 2015 (15.6%, 537/5327, 95%CI 5.7 – 29.2%) compared to data collected between 2016 and 2025 (17.2%, 587/3326, 95%CI 8.3 – 28.4%). The highest pooled estimates were found in the town of Yaoundé (27.6%, 474/1884, 95%CI 11.8 – 47.1%), followed by Buea (23.6%, 367/2848, 95%CI 0.8 – 63.5%), and Douala (14.2%, 177/1314, 95%CI 7.6 – 22.5%). Higher estimates were found using PBF compared to RDT (17.0% vs 11.7%, p < 0.001) and large-sized studies compared to small-sized studies (17.6% vs 16.3%, p < 0.001) (S1 Fig). Co-infection patterns Co-infections between major and ‘neglected’ blood-borne pathogens were reported in four studies [16,21,26,27]. In Douala (Littoral region), Okalla Ebongue et al. found 8 co-infections represented by HBV + P. falciparum (n = 3, 1.2%), T. pallidum + P. falciparum (n = 3, 1.2%), HCV + P. falciparum (n = 1, 0.4%), and HIV + T. pallidum + P. falciparum (n = 1, 0.4%) [26]. Focusing on the HTLV-1, Okalla Ebongue et al. found 3 co-infections of this virus with HBV (n = 1, 0.37%), HIV (n = 1, 0.37%), and T. pallidum (n = 1, 0.37%) in Yaoundé (Centre region) [27]. In Bamenda (Northwest region), two co-infections, i.e., T. pallidum + P. falciparum (n = 1, 0.20%) and HCV + P. falciparum (n = 1, 0.20%), were reported by Fondoh et al. [16], while Tchoffo et al. reported the co-infection T. gondii + P. falciparum at a rate of 0.9% (n = 3) [16]. Residual risk Only one study evaluated the residual risk associated with TTIs, especially Plasmodium spp.-related risk [27]. Okalla Ebongue et al. found an individual median residual risk of 5.59 per 10,000 units of blood transfused every year in Douala [27]. Associated factors The associated factors with ‘neglected’ TTIs (i.e., Plasmodium spp.) or putative TTIs (i.e., SARS-CoV-2) were investigated in three studies. In Douala (Littoral region), Medi Sike et al. reported higher odds of SARS-CoV-2 infection in donors aged 18 – 28 years (cOR = 3.55, p < 0.0001) and 28 – 38 years (cOR = 2.14, p < 0.0001) compared to those aged 48 – 58 years [17]. In contrast, Ndoumba et al. reported a lower risk of SARS-CoV-2 infection in blood donors aged 35 – 44 years (aOR = 0.44, p = 0.039) compared to those aged < 25 years in Bamenda (Northwest region) [18]. In Douala, Ndo et al. reported that the risk of P. falciparum infection was reduced by ~80% (cOR = 0.71, p < 0.0001) among donors sleeping under long-lasting insecticide-treated nets compared with those without them [28]. Clinical and biological impact of neglected TTIs in donors and recipients Three studies addressed the clinical impact of TTIs, two on malaria and one on malaria and toxoplasmosis [15,20,21]. In Bafoussam (West region), although not reaching statistical significance, Ewodo et al. reported that all Plasmodium spp.-infected erythrocyte concentrates failed to meet blood safety and quality standards. Addressing the effect of hemoparasites on immunoglobulin E and albumin, Tchoffo et al. have noticed higher immunoglobulin E levels (p = 0.0001) in Plasmodium-infected donors. Likewise, T. gondii-infected donors had higher immunoglobulin E levels (p = 0.026) and lower albumin levels (p = 0.037) [21]. Finally, based on a longitudinal study in the city of Dschang (West region), Djam Chefor et al. found that 4 of the 6 recipients who had received Plasmodium-infected blood were positive for malaria. Of the 44 recipients included, the post-transfusion malaria incidence was estimated at 9.09% [20]. Discussion Blood supply is already a public issue in African countries. This section summarizes the most urgent challenges associated with ‘neglected’ TTIs in Cameroon. The reviewed studies were mainly conducted in three regions (i.e., Centre, Littoral, and Northwest). This regional gap, pinpointed in the present study, is the missing link to understanding the epidemiology of these ‘neglected’ TTIs, and this warrants the need for further studies in the country, especially in regions with little or no data. The reviewed studies were mainly conducted in three regions (i.e., Centre, Littoral, and Northwest). This regional gap, pinpointed in the present study, is the missing link to understanding the epidemiology of these ‘neglected’ TTIs, and this warrants the need for further studies in the country, especially in regions with little or no data. The lack of data on these ‘neglected’ TTIs, as well as field evidence, especially for dengue, HTLV-1, or filariasis, is the main challenge. In the present SRMA, we have shown that pooled estimates of Plasmodium spp. and T. gondii infections can be similar to or exceed those of major TTIs. This assumption is supported by findings of a recent SRMA of major blood-transmitted pathogens in Cameroon, which reported pooled proportions of 2.4%, 8.9%, 2.2%, and 3.6% for HIV, HBV, HCV, and T. pallidum, respectively [5]. There are limited or no data on the epidemiology of the above-mentioned non-malarial pathogens (i.e., dengue virus, HTLV-1, filariae). Such epidemiological data are instrumental in evaluating the real danger posed by these pathogens and in guiding blood safety policies in blood transfusion services. The lack of data on these ‘neglected’ TTIs, as well as field evidence, especially for dengue, HTLV-1, or filariasis, is the main challenge. In the present SRMA, we have shown that pooled estimates of Plasmodium spp. and T. gondii infections can be similar to or exceed those of major TTIs. This assumption is supported by findings of a recent SRMA of major blood-transmitted pathogens in Cameroon, which reported pooled proportions of 2.4%, 8.9%, 2.2%, and 3.6% for HIV, HBV, HCV, and T. pallidum, respectively [5]. There are limited or no data on the epidemiology of the above-mentioned non-malarial pathogens (i.e., dengue virus, HTLV-1, filariae). Such epidemiological data are instrumental in evaluating the real danger posed by these pathogens and in guiding blood safety policies in blood transfusion services. In individuals qualified for blood donations following screening for major pathogens, these ‘neglected’ pathogens exist asymptomatically, often at low density malaria infections (LDMIs) [31], can be transmitted to recipients and then elicit a clinical episode. It should be interesting to conduct clinical impact and longitudinal studies in recipients in future to inform healthcare personnel and policymakers. These would be helpful to assess the fraction of Plasmodium spp. infections attributed to blood transfusion, as well as their clinical impact. In individuals qualified for blood donations following screening for major pathogens, these ‘neglected’ pathogens exist asymptomatically, often at low density malaria infections (LDMIs) [31], can be transmitted to recipients and then elicit a clinical episode. It should be interesting to conduct clinical impact and longitudinal studies in recipients in future to inform healthcare personnel and policymakers. These would be helpful to assess the fraction of Plasmodium spp. infections attributed to blood transfusion, as well as their clinical impact. It is well known that the infectious risk varies by blood donor types (family, paid, voluntary) for primarily targeted TTIs (e.g., viral hepatitis), with the highest risks commonly reported in family donors. This aspect was recently reported in an earlier investigation in Cameroon [5]. In the present study, it was tricky to address the patterns of the proportion of Plasmodium spp. infections by type of donor, and this outlines the need for further studies to address this aspect. The current available data on the association between Plasmodium spp. infections and donor type are conflicting. For instance, no significant association was found in Nigeria [32], while in Saudi Arabia, a higher risk of Plasmodium spp. infections in family donors compared to voluntary donors [33]. It is well known that the infectious risk varies by blood donor types (family, paid, voluntary) for primarily targeted TTIs (e.g., viral hepatitis), with the highest risks commonly reported in family donors. This aspect was recently reported in an earlier investigation in Cameroon [5]. In the present study, it was tricky to address the patterns of the proportion of Plasmodium spp. infections by type of donor, and this outlines the need for further studies to address this aspect. The current available data on the association between Plasmodium spp. infections and donor type are conflicting. For instance, no significant association was found in Nigeria [32], while in Saudi Arabia, a higher risk of Plasmodium spp. infections in family donors compared to voluntary donors [33]. RDT and PBF are the main techniques used in health facilities in Cameroon. Even though blood bank personnel are aware of malaria risk, Plasmodium spp. parasites can still be missed during screening with RDTs due to false negative results for reasons such as LDMIs, non-P. falciparum species (e.g., P. vivax, P. ovale spp.), and the presence of P. falciparum parasites with deletions in the histidine-rich protein 2 (pfhrp2) gene. The bulk of commercial RDTs are designed to target the histidine-rich protein 2, which is only produced by P. falciparum parasites [34]. The emergence and spread of pfhrp2-deleted P. falciparum parasites is a threat to RDT-based diagnosis, given the ability of these parasites to escape PfHRP2-targeting RDTs, and thus leading to false negative RDT results [35]. Several Cameroonian authors have reported these threats in the territory [36,37]. Additionally, cost and resource constraints associated with PBF are cumbersome, thereby reducing the likelihood of additional testing at blood banks. Personnel at blood banks in Cameroon and other African countries are facing significant work-related pressure. In such settings, priority is often given to mandatory tests for the major TTIs (e.g., HIV, HBV, HCV, and syphilis) in the country. The introduction of additional tests, such as those for Plasmodium spp. parasite detection requires more time, resources, and technical capacity. Thus, testing of neglected TTIs is not routinely performed at blood banks of developing settings, such as Cameroon. Besides, point-of-care molecular tests (e.g., Truenat) are available and have shown promising field performance in detecting P. falciparum and P. vivax LDMIs in other malaria-endemic settings [38]. In this context, it would be interesting to reinforce blood safety via the integration of these point-of-care molecular diagnostic approaches. It is also needed to improve quality assurance systems, enhance staff training, and ensure adequate resource allocation for malaria screening in blood banks. These call for cost-effectiveness and qualitative studies to evaluate the potential impact of these solutions in the Cameroonian context. RDT and PBF are the main techniques used in health facilities in Cameroon. Even though blood bank personnel are aware of malaria risk, Plasmodium spp. parasites can still be missed during screening with RDTs due to false negative results for reasons such as LDMIs, non-P. falciparum species (e.g., P. vivax, P. ovale spp.), and the presence of P. falciparum parasites with deletions in the histidine-rich protein 2 (pfhrp2) gene. The bulk of commercial RDTs are designed to target the histidine-rich protein 2, which is only produced by P. falciparum parasites [34]. The emergence and spread of pfhrp2-deleted P. falciparum parasites is a threat to RDT-based diagnosis, given the ability of these parasites to escape PfHRP2-targeting RDTs, and thus leading to false negative RDT results [35]. Several Cameroonian authors have reported these threats in the territory [36,37]. Additionally, cost and resource constraints associated with PBF are cumbersome, thereby reducing the likelihood of additional testing at blood banks. Personnel at blood banks in Cameroon and other African countries are facing significant work-related pressure. In such settings, priority is often given to mandatory tests for the major TTIs (e.g., HIV, HBV, HCV, and syphilis) in the country. The introduction of additional tests, such as those for Plasmodium spp. parasite detection requires more time, resources, and technical capacity. Thus, testing of neglected TTIs is not routinely performed at blood banks of developing settings, such as Cameroon. Besides, point-of-care molecular tests (e.g., Truenat) are available and have shown promising field performance in detecting P. falciparum and P. vivax LDMIs in other malaria-endemic settings [38]. In this context, it would be interesting to reinforce blood safety via the integration of these point-of-care molecular diagnostic approaches. It is also needed to improve quality assurance systems, enhance staff training, and ensure adequate resource allocation for malaria screening in blood banks. These call for cost-effectiveness and qualitative studies to evaluate the potential impact of these solutions in the Cameroonian context. Many co-infection cases were reported across the reviewed studies, mainly P. falciparum with viral infections (i.e., HBV, HCV, HIV). These viral infections, especially HIV, are well known to be a risk factor for malaria severity and deaths [39,40]. Conversely, Plasmodium spp. infection is associated with higher HIV viral load and inflammatory responses [39,40]. In a context where persons living with HIV, which could also include pregnant women, can also benefit from blood transfusion, preventing transfusion-transmitted malaria is crucial. In addition, even though limited evidence is available on the impact of anti-retroviral treatment on P. falciparum-related antimalarial drug treatment efficacy [41], it is still important to prevent post-transfusion P. falciparum malaria in HIV-infected recipients. Many co-infection cases were reported across the reviewed studies, mainly P. falciparum with viral infections (i.e., HBV, HCV, HIV). These viral infections, especially HIV, are well known to be a risk factor for malaria severity and deaths [39,40]. Conversely, Plasmodium spp. infection is associated with higher HIV viral load and inflammatory responses [39,40]. In a context where persons living with HIV, which could also include pregnant women, can also benefit from blood transfusion, preventing transfusion-transmitted malaria is crucial. In addition, even though limited evidence is available on the impact of anti-retroviral treatment on P. falciparum-related antimalarial drug treatment efficacy [41], it is still important to prevent post-transfusion P. falciparum malaria in HIV-infected recipients. Training of health personnel of blood banks for the screening of these ‘neglected’ pathogens is essential. Awareness campaigns and periodical training sessions should be implemented and/or scaled up to increase testing rates for these ‘neglected’ pathogens. A recent study by Nguemnang et al. pinpointed very low testing rates for Plasmodium spp. and T. gondii in blood donors (7% and 4.7%) and recipients (0% and 2.3%) of health facilities in the West region [42]. Training of health personnel of blood banks for the screening of these ‘neglected’ pathogens is essential. Awareness campaigns and periodical training sessions should be implemented and/or scaled up to increase testing rates for these ‘neglected’ pathogens. A recent study by Nguemnang et al. pinpointed very low testing rates for Plasmodium spp. and T. gondii in blood donors (7% and 4.7%) and recipients (0% and 2.3%) of health facilities in the West region [42]. Targeting additional pathogens could worsen the blood supply and increase the risk of shortages. There is a balance to find between blood supply and safety. For malaria, it was proposed to give recipients a preventive antimalarial drug. Currently available data indicate a very low rate (9.1%) of prophylactic treatment for post-transfusion malaria in Cameroon health facilities [20]. However, to be more effective, this approach requires access to updated data on drug resistance epidemiology and therapeutic efficacy studies. Targeting additional pathogens could worsen the blood supply and increase the risk of shortages. There is a balance to find between blood supply and safety. For malaria, it was proposed to give recipients a preventive antimalarial drug. Currently available data indicate a very low rate (9.1%) of prophylactic treatment for post-transfusion malaria in Cameroon health facilities [20]. However, to be more effective, this approach requires access to updated data on drug resistance epidemiology and therapeutic efficacy studies. Limitations The findings of the present SRMA should be interpreted in light of its limitations. First, the limited number of data, most of which came from the Littoral, Northwest, and Centre regions, hindered our ability to generalize our findings to the rest of the regions. Second, we found substantial between-study heterogeneity in meta-analyses. Furthermore, this heterogeneity is likely to arise from differences in study design, population characteristics, geographic coverage, and diagnostic method, and thus, these differences may have influenced the pooled proportion estimates. Indeed, it is well known that the Plasmodium spp. transmission is seasonal in several regions of Cameroon [43]. Given the fact that the data collection period varied across the included studies, this may also explain the high between-study heterogeneity observed in the present study. This high heterogeneity is common in meta-analyses of proportions [44]. Third, even though peer-reviewed, we have noticed that several studies were published in poor-quality journals. In general, there is a strong correlation between reviewing rigor and journal quality. Fourth, the few studies that addressed determinants of ‘neglected’ TTIs have negatively impacted evidence synthesis. Finally, for the handful of studies that have also included recipients, it was not clear if Plasmodium spp. infections were due to natural transmission or blood transfusion. Malaria is highly endemic in Cameroon [45]. In such contexts, recipients may acquire infection through mosquito exposure independent of transfusion. Relevant included studies have traced back the origin of Plasmodium spp. infections in recipients by performing a pre-transfusion screening, follow-up, and RDT-based testing. As discussed earlier, it is possible that the recipients were already infected with Plasmodium spp. parasites before transfusion, with parasites present at densities below the limit of detection of the screening tests. These facts also constitute a limitation of our study. Conclusion This study was designed to conduct a systematic review and meta-analysis of less prioritized blood-borne pathogens in blood blanks of Cameroon. The study revealed a dearth of epidemiological data, with an overrepresentation in three regions of the country. The prevalence of pathogens, such as Plasmodium spp. and T. gondii, can often outnumber that of major TTIs. Also, we argue that the most critical challenge is to produce high-quality epidemiological data on the residual risk, burden, extent, and determinants of these ‘neglected’ transfusion-transmitted pathogens. Disposing of such data is pivotal to addressing the other challenges identified in the review. Supporting information PRISMA 2020 Checklist. (DOCX) Bias risk assessment of the included studies. (DOCX) Subgroup analysis, sensitivity analysis, and publication bias of studies on malaria in blood donors. (DOCX) 5 Apr 2026 -->PNTD-D-26-00009 Burden and clinical impact of ‘neglected’ transfusion-transmitted infections in Cameroon: a systematic review and meta-analysis PLOS Neglected Tropical Diseases Dear Dr. Foko, Thank you for submitting your manuscript to PLOS Neglected Tropical Diseases. After careful consideration, we feel that it has merit but does not fully meet PLOS Neglected Tropical Diseases's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript within by Jun 04 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosntds@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pntd/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: * A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below. * A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. * An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. We look forward to receiving your revised manuscript. Kind regards, Rana Nagarkatti Guest Editor PLOS Neglected Tropical Diseases Hira Nakhasi Section Editor PLOS Neglected Tropical Diseases Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-4304-636XX Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-1765-0002 Additional Editor Comments: Dear Dr. Foko, Thank you for submitting your manuscript for review to PLoS NTD. Although you have addressed an important public health issue in Cameroon, the manuscript has significant issues related to description of data, limitations, and analysis of the underlying studies. In addition to the issues raised by the reviewers, please address the following: 1. On line 212-213, you state that “94.4% of the studies failed to provide site details (i.e., related to blood transfusion), and 66.7% did not use an appropriate statistical analysis” with the study details provided in S2 Table. a. This is a significant issue as it raises questions on the conclusion drawn and the information presented in Table 1. Please move the column on site details and appropriate statistical analysis from S2 Table to Table 1. b. Please provide appropriate descriptive titles for the tables. c. The limitations section of your manuscript lacks detail and does not attribute limitations to various factors addressed in S2 Table. The limitations section needs to be re-written. 2. For proportions provided, e.g., line 247 for pooled estimates of Plasmodium infection 15.6%, please provide the numerator and denominator in addition to the percentage and 95% CI. 3. Table 1 shows the donor selection criteria for all donors together (family, voluntary, and paid). The three categories have different risk profiles as blood donors with respect to TTIs. Although there is limited data, does the risk profile vary for these three groups regarding Malaria transmission e.g., paid donors may not have access to Malaria preventive measures, and therefore would be a higher risk? Is it possible to evaluate the three groups separately based on the available literature? 4. Although Plasmodium parasite was the major pathogen based on your inclusion criteria for publications, please provide data on HIV, HCV, and HBV, as it will help readers understand the scope of the issue better when compared to viral TTIs. Viral TTI data may not necessarily be an analysis of excluded publication but from existing literature. 5. Malaria transmission varies by season. Transmission may have also declined due to control programs. a. Based on the limited number of publications, please address how these two factors impact your study. b. Additionally, considering that the donors and recipients reside in a Malaria endemic area, you have not addressed the possibility that recipients may have tested positive due to transmission by a mosquito bite rather than by blood transfusion from a false negative tested donor. From the selected literature, please describe how traceback studies were performed to attribute blood donors to recipients testing positive for Plasmodium. Significant confounding factors exist and may have been addressed in the selected studies, however, these should also be addressed, either in the discussion section or in the limitations section of your manuscript. 6. Please consider providing a map of Camerron along with Table 1 so it is easier for readers to visualize where the studies were performed. What proportion of the country (area and population) is covered by the analysis performed? This is an important factor to analyze considering the impact on public health policy of your manuscript. Best regards, Rana Nagarkatti Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 1) Please provide an Author Summary. This should appear in your manuscript between the Abstract (if applicable) and the Introduction, and should be 150-200 words long. The aim should be to make your findings accessible to a wide audience that includes both scientists and non-scientists. Sample summaries can be found on our website under Submission Guidelines: https://journals.plos.org/plosntds/s/submission-guidelines#loc-parts-of-a-submission 2) Please upload all main figures as separate Figure files in .tif or .eps format. For more information about how to convert and format your figure files please see our guidelines: https://journals.plos.org/plosntds/s/figures 3) We note that your Data Availability Statement is currently as follows: "Not applicable.". Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition). For example, authors should submit the following data: 1) The values behind the means, standard deviations and other measures reported; 2) The values used to build graphs; 3) The points extracted from images for analysis.. Authors do not need to submit their entire data set if only a portion of the data was used in the reported study. If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories. If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access. 4) As required by our policy on Data Availability, please ensure your manuscript or supplementary information includes the following: - A numbered table of all studies identified in the literature search, including those that were excluded from the analyses. - For every excluded study, the table should list the reason(s) for exclusion. - If any of the included studies are unpublished, include a link (URL) to the primary source or detailed information about how the content can be accessed. - A table of all data extracted from the primary research sources for the systematic review and/or meta-analysis. The table must include the following information for each study: - Name of data extractors and date of data extraction - Confirmation that the study was eligible to be included in the review. - All data extracted from each study for the reported systematic review and/or meta-analysis that would be needed to replicate your analyses. - If data or supporting information were obtained from another source (e.g. correspondence with the author of the original research article), please provide the source of data and dates on which the data/information were obtained by your research group. - If applicable for your analysis, a table showing the completed risk of bias and quality/certainty assessments for each study or outcome. Please ensure this is provided for each domain or parameter assessed. For example, if you used the Cochrane risk-of-bias tool for randomized trials, provide answers to each of the signalling questions for each study. If you used GRADE to assess certainty of evidence, provide judgements about each of the quality of evidence factor. This should be provided for each outcome. - An explanation of how missing data were handled. This information can be included in the main text, supplementary information, or relevant data repository. Please note that providing these underlying data is a requirement for publication in this journal, and if these data are not provided your manuscript might be rejected. Reviewers' Comments: Reviewer's Responses to Questions Key Review Criteria Required for Acceptance? As you describe the new analyses required for acceptance, please consider the following: Methods -Are the objectives of the study clearly articulated with a clear testable hypothesis stated? -Is the study design appropriate to address the stated objectives? -Is the population clearly described and appropriate for the hypothesis being tested? -Is the sample size sufficient to ensure adequate power to address the hypothesis being tested? -Were correct statistical analysis used to support conclusions? -Are there concerns about ethical or regulatory requirements being met? Reviewer #1: The objectives of the study were clearly articulated. The study design is appropriate. The authors performed systematic review and meta-analyses on the studies investigating transfusion transmitted infections already published in peer-reviewed journals. The targeted population resides in Cameroon. Authors chose appropriate statistical analyses which supported conclusions of the study. No ethical concerns were noticed. Reviewer #2: (No Response) Reviewer #3: Please see Summary and General Comments ********** Results -Does the analysis presented match the analysis plan? -Are the results clearly and completely presented? -Are the figures (Tables, Images) of sufficient quality for clarity? Reviewer #1: The results are clearly presented with legible figures and tables. Reviewer #2: 1. Need to provide description of each sub-figure. Reviewer #3: Please see Summary and General Comments ********** Conclusions -Are the conclusions supported by the data presented? -Are the limitations of analysis clearly described? -Do the authors discuss how these data can be helpful to advance our understanding of the topic under study? -Is public health relevance addressed? Reviewer #1: The data supported conclusions except T. gondii. Authors described the limitations of the study. Reviewer #2: Yes, conclusion supported by the data presented and public health relevance addressed. Reviewer #3: Please see Summary and General Comments ********** Editorial and Data Presentation Modifications? Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”. Reviewer #1: Introduction Line 47: Please indicate all four viral and bacterial pathogens Line 83: Please indicate the duration of blood donations recorded by WHO Line 101: Please indicate regions where priority is given for 4 pathogens described. Line 108-109: Please indicate the location of health facilities and provide specifics about countries implementing national blood safety policies and surveillance Line 115: Please describe in 1-2 sentences on what aspects the mentioned pathogens are being neglected in developing countries. Material Methods Line 128: Though authors stated no ethical authorization is required for the current study, please indicate if any ethical considerations were followed in your protocol while handling the data from previous literature. Line 161: Please indicate whether the three reviewers (mentioned in line 156) and three authors (mentioned in Line 161) are same. Line 167: Please indicate how many reviewers assessed methodological quality of each study and whether they worked independently. Line 169: Clarify the sentence structure. Findings from the included studies or SRMA of the included studies? Expand the abbreviation SRMA and indicate that the SRMA mentioned is the current study. Results Line 195: Please indicate the dates of data collection for identified records Line 199: Please clarify whether you identified two or three papers after inspection of bibliographies. Line 211: Please indicate all four criteria for which bias risk of the studies was good. Discussion Line 297: Please indicate the pooled estimates of major TTIs in Cameroon for comparison. Please clarify whether the statement is true for T. gondii infections. You did not provide a pooled estimate for T. gondii infection in Results section. Line 300: Please indicate the non-malarial pathogens that you are discussing. Line 301: So far, there is no empirical evidence presented for SARS-CoV-2 causing transfusion-transmitted infections. Therefore, discussing SARS-CoV-2 with relevant to TTI is not necessary. Please remove this sentence. Line 317: Please elaborate why deletions in the histidine-rich protein 2 genes are important for false negative results in RDTs. Line 321: Please elaborate how significant work-related pressure faced by personnel at blood banks in Cameroon affect the likelihood of additional testing for malaria in blood donors Conclusion Line 356: please clarify how T. gondii prevalence outnumber that of major TTIs. Supporting information S1 Table, Introduction, Objectives, item # 4: Please revise as “Introduction, 3rd and 4th paragraph” under the location where item is reported Figures Figure 1: Please remove SARS-CoV2 from the data as there is no empirical evidence presented for this pathogen causing transfusion-transmitted infections. Table S1: Item#26, under location where item is reported, please revise the title to “Competing interests”. Item#27, under location where item is reported, please revise the title to “Data availability statement” and indicate that it is not applicable. Reviewer #2: (No Response) Reviewer #3: Please see Summary and General Comments ********** Summary and General Comments Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed. Reviewer #1: The authors performed a systematic review and meta-analysis to assess the burden and clinical impact of ‘neglected’ transfusion-transmitted infections in Cameroon. The authors identified Plasmodium parasite is the major studied pathogen even though an evident publication bias was found. The pooled proportion of Plasmodium spp. infections was 16.6% and substantial between-study heterogeneity was found. The authors indicated paucity of clinical impact studies for Plasmodium and other neglected transfusion-transmitted infections in Cameroon. Reviewer #2: 1. In 64, you noted that "The pooled proportions of infection in blood donors were 16.6% for Plasmodium spp., 17.7% for SRAS-CoV-2, and 0.5% for Loa loa". Please clarify, if SARS-CoV-2 is transfusion transmitted. 2. Please provide a discussion on what can be done to mitigate the knowledge gap in real-life case vs different data bases. Reviewer #3: In this manuscript, Malieuze Nanfah et al., provide a review of the burden and clinical impact of some neglected transfusion transmitted infections in the country of Cameroon, Africa. The authors performed a systematic literature review and meta-analysis of prevalence, determinants and clinical impact of pathogens not included in the blood safety guidelines in blood banks in Cameroon, referred as “neglected” in this manuscript (e.g. filaria, dengue virus, Toxoplasma gondii). The authors identified the most urgent challenges and proposed actionable solutions to guide blood safety guidelines in the country. General comments 1) While this meta-analysis is constrained by a limited number of eligible studies, the scarcity of data is itself a significant finding. Further, as mentioned by the authors, as the available research is restricted to three regions of Cameroon, the results may not be fully generalizable to the national level. These limitations are addressed in the discussion; however, documenting this regional data gap is a primary contribution of this report and warrants publication. 2) Considering the limitations of the studies, the authors identified challenges which should be addressed to improve blood safety in Cameroon. These include awareness of neglected diseases among healthcare providers and policymakers, diagnostic and logistical constraints, and low grade infections. The authors should address the following comments in their revised manuscript: 3) Line 65: Define the abbreviation “TTIs” in the abstract 4) Line 152: Please explain why publications prior to 2006 were excluded for this analysis. 5) Line 208: Please clarify the meaning of “accidentally found” in the context of the 2 published studies. 6) Lines 254-263: Please discuss the impact of these co-infections on blood safety. 7) Lines 313-324: While this paragraph underscores the operational challenges and limited efficacy associated with RDT and PBF testing, a clear statement regarding the authors' proposed solution is currently missing. Explicitly detailing these improvements would clarify the study's contribution. 8) Line 322: Please briefly explain the “significant work-related pressure” experienced by personnel at blood banks in Cameroon. ********** PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No Figure resubmission: While revising your submission, we strongly recommend that you use PLOS’s NAAS tool (https://ngplosjournals.pagemajik.ai/artanalysis) to test your figure files. NAAS can convert your figure files to the TIFF file type and meet basic requirements (such as print size, resolution), or provide you with a report on issues that do not meet our requirements and that NAAS cannot fix. --> After uploading your figures to PLOS’s NAAS tool - https://ngplosjournals.pagemajik.ai/artanalysis, NAAS will process the files provided and display the results in the "Uploaded Files" section of the page as the processing is complete. If the uploaded figures meet our requirements (or NAAS is able to fix the files to meet our requirements), the figure will be marked as "fixed" above. If NAAS is unable to fix the files, a red "failed" label will appear above. When NAAS has confirmed that the figure files meet our requirements, please download the file via the download option, and include these NAAS processed figure files when submitting your revised manuscript.--> Reproducibility: To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols --> 20 Apr 2026 Submitted filename: Response to Reviewers.docx 14 May 2026 Dear Dr. Foko, We are pleased to inform you that your manuscript 'Burden and clinical impact of ‘neglected’ transfusion-transmitted infections in Cameroon: a systematic review and meta-analysis' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases. Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests. Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated. IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript. Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS. Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases. Best regards, Rana Nagarkatti Guest Editor PLOS Neglected Tropical Diseases Hira Nakhasi Section Editor PLOS Neglected Tropical Diseases Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-4304-636XX Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-1765-0002 *********************************************************** p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; line-height: 16.0px; font: 14.0px Arial; color: #323333; -webkit-text-stroke: #323333}span.s1 {font-kerning: none Reviewer's Responses to Questions Key Review Criteria Required for Acceptance? As you describe the new analyses required for acceptance, please consider the following: Methods -Are the objectives of the study clearly articulated with a clear testable hypothesis stated? -Is the study design appropriate to address the stated objectives? -Is the population clearly described and appropriate for the hypothesis being tested? -Is the sample size sufficient to ensure adequate power to address the hypothesis being tested? -Were correct statistical analysis used to support conclusions? -Are there concerns about ethical or regulatory requirements being met? Reviewer #1: (No Response) Reviewer #3: The authors have adequately addressed my comments/question in their revised manuscript. ********** Results -Does the analysis presented match the analysis plan? -Are the results clearly and completely presented? -Are the figures (Tables, Images) of sufficient quality for clarity? Reviewer #1: (No Response) Reviewer #3: The authors have adequately addressed my comments/question in their revised manuscript. ********** Conclusions -Are the conclusions supported by the data presented? -Are the limitations of analysis clearly described? -Do the authors discuss how these data can be helpful to advance our understanding of the topic under study? -Is public health relevance addressed? Reviewer #1: (No Response) Reviewer #3: The authors have adequately addressed my comments/question in their revised manuscript. ********** Editorial and Data Presentation Modifications? Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”. Reviewer #1: (No Response) Reviewer #3: The authors have adequately addressed my comments/question in their revised manuscript. I recommend this revised manuscript for publication. Minor comment: "TTI" should be defined the first time it is used in the abstract ********** Summary and General Comments Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed. Reviewer #1: (No Response) Reviewer #3: The authors have adequately addressed my comments/question in their revised manuscript. ********** PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #3: No Dear Dr Kojom Foko, We are delighted to inform you that your manuscript, "Burden and clinical impact of ‘neglected’ transfusion-transmitted infections in Cameroon: a systematic review and meta-analysis," has been formally accepted for publication in PLOS Neglected Tropical Diseases. We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication. The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly. Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers. For Research Articles, you will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases. Best regards, Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases